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Strengths and limitations of this study
 ► The use of qualitative methodology captured the 
complex processes behind people’s perspectives 
of general practice pharmacists (GPPs), including 
how lived experiences shaped opinions of new 
pharmacist- led services.
 ► Telephone- based interviews enabled recruitment 
across the UK and increased study accessibility for 
people with severe asthma and travel limitations.
 ► The study may not have captured the full variation in 
views among adults with asthma in the UK because 
participants primarily had self- reported mild asthma 
and were recruited through an asthma charity.
 ► Participants had no experience with GPP- led consul-
tations and therefore represented the general pop-
ulation with asthma that would initially need to be 
convinced to engage with the service.
AbStrACt
Objectives The National Health Service (NHS) in England 
recently introduced general practice pharmacists (GPPs) 
to provide medication- focused support to both patients 
and the general practice team. This healthcare model 
may benefit people with asthma, who currently receive 
suboptimal care and demonstrate low medication 
adherence. This study aimed to explore the perspectives 
of adults with asthma on the potential for pharmacist- led 
adherence support delivered in general practice, with a 
focus on how these perspectives are formed.
Design and setting The study was conducted in the 
United Kingdom (UK) utilising a qualitative interview 
methodology. Participants were invited to partake in a 
telephone- based semistructured interview, followed by an 
online questionnaire for demographic details and asthma 
history. Qualitative data were analysed using thematic 
analysis.
Participants Participants (n=17) were adults with asthma 
in the UK with a prescription for an inhaled corticosteroid. 
Participants did not have previous experience with GPPs 
and were asked to provide their views on a proposed GPP- 
led service.
results Participant perspectives of GPPs were determined 
by trust in pharmacists, perceived gaps in asthma care 
and the perceived strain on the NHS. Trust was based on 
pharmacists’ perceived clinical competency, established 
over time, and gauged through a ‘benchmarking’ process. 
GPP’s fit in current asthma care was assessed based on 
potential role overlap with other healthcare professionals, 
continuity of care and medication- related support needs. 
Participants navigated the NHS based on a perceived 
hierarchy of healthcare professionals (general practitioners 
on top, nurses, then pharmacists), and this influenced their 
perspectives of GPPs.
Conclusion While the GPP scheme shows promise based 
on the perspectives of people with asthma, the identified 
barriers to optimal patient engagement and service 
implementation will need to be addressed for the service 
to be effective.
bACkgrOunD
The pressure on primary care to deliver core 
services is increasing rapidly worldwide due to 
a growing and ageing population, the preva-
lence of long- term conditions and significant 
resource constraints. Primary care systems are 
being reshaped, and new models of care are 
emerging to cope with growing demand.1
One such model is the general practice 
pharmacist (GPP) model, which was intro-
duced in England as part of the NHS General 
Practice Forward View initiative.2–4 These 
pharmacists support both the patients and 
the general practice team with medication- 
related issues, with the aim of expanding the 
general practice workforce, reducing prac-
tice burden and increasing patient access to 
appointments.4 Initial qualitative feedback 
from general practitioners (GPs) and phar-
macists in a pilot study in England suggests 
that GPPs can have positive impacts on medi-
cation safety, medication adherence, health-
care access and patient satisfaction across a 
variety of long- term conditions.3
People with asthma may benefit from GPP 
support. Research shows that adherence to 
inhaled corticosteroids (ICS), an essential 
medication for asthma, is low.5 6 Furthermore, 
only 35% of people with asthma in the UK 
receive basic care (ie, annual reviews, inhaler 
technique checks and a written asthma 
action plan).7 Previous research suggests that 
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pharmacist- led interventions can increase medication 
adherence and support asthma self- management among 
people with asthma.8 However, most of the previous 
research in the UK has been limited to community rather 
than GPPs and focused on their impact across a range of 
long- term conditions rather than asthma specifically.9 10
Understanding the specific perspectives of people with 
asthma regarding GPPs is an important first step in estab-
lishing the potential benefits of this new service for this 
specific patient group, as well as identifying any potential 
issues in its future uptake and effectiveness.11 The aim of 
this study was to explore the perspectives of adults with 
asthma on the potential of pharmacist- led asthma adher-
ence support delivered in general practice, with a focus 
on how these perspectives are formed.
MethODS
This study is reported according to the Standards for 
Reporting Qualitative Research.12 It was a telephone- 
based semistructured interview study, using an interpre-
tivist approach to understand how adults with asthma 
construct their initial opinions of GPP- led asthma adher-
ence support. Demographic details and asthma history 
were collected using a brief online questionnaire.
Participants
Participants were adults (≥18 years old) living in the UK 
and proficient in English, with a self- reported asthma 
diagnosis, a prescription for ICS and access to a telephone 
and e- mail account. People with respiratory comorbidi-
ties (eg, Chronic Obstructive Pulmonary Disease) and/or 
those in hospital or nursing homes were excluded, as the 
adherence behaviour and support needs of these individ-
uals were hypothesised to be different.
recruitment
Several recruitment channels were used to ensure that 
participants varied in age, gender and self- reported 
asthma severity. A flyer with study information and 
researchers’ contact details was circulated by researchers, 
the Asthma UK Centre for Applied Research (AUKCAR) 
and the National Institute for Health Research Collabora-
tion for Leadership in Applied Health Research and Care 
North Thames via social media. The study was advertised 
in two electronic newsletters: the Asthma UK volunteer 
bulletin and the University College London student 
newsletter. Printed flyers were handed directly to poten-
tial participants by a respiratory consultant at a London 
hospital and pharmacists at two hospitals in Wales.
People who contacted the researchers were e- mailed 
an information sheet, consent form and eligibility 
criteria to review. If they were eligible and willing to 
participate, they were booked in for a 1- hour telephone 
interview. In preparation for the call, participants 
were asked to read a description of a GPP- led adher-
ence support consultation, sent to them via e- mail (see 
online supplementary appendix A). This description 
was based on the work of a clinical respiratory phar-
macist working in general practice in London. Partici-
pants gave verbal consent over the telephone before the 
interview began. The consent procedure and interview 
were audio- recorded with their permission. All partici-
pants received a £20 online shopping voucher to thank 
them for their time.
Data collection and analysis
One researcher (MAM) conducted the interviews. Partic-
ipants were informed that the researcher had a back-
ground in Health Psychology and an interest in adherence 
and pharmacist- led care for asthma.
The interview topic guide had two sections (see online 
supplementary appendix B). The first section focused 
on participants’ previous experiences of asthma, asthma 
care and pharmacists. The second section focused on 
how these lived experiences informed participants’ 
opinions of GPP- led adherence support, with questions 
based on previous research on interpersonal/institu-
tional trust in healthcare professionals,13 14 perceptions 
of the pharmacist role15–17 and pharmacist- led care for 
asthma.10 18–20
Participants also completed an online questionnaire on 
demographic details (gender and age) and asthma history 
(self- reported asthma severity, hospitalisations and GP 
visits). An online questionnaire was used because partic-
ipants may have felt uncomfortable disclosing personal 
information (eg, age) directly to a researcher during 
the telephone call. The self- report method was chosen 
because recruitment to the study may have been difficult 
if access to participants’ medical records was required.
All interviews were professionally transcribed, with 
transcripts checked for accuracy by MAM. Data were anal-
ysed using NVivo (QSR, V.11). Thematic analysis was used 
to identify themes at the semantic level using a deductive 
approach, based on their relevance to the study aim.21 
Continuous iterative analyses were conducted to estab-
lish when thematic saturation had been reached. Recruit-
ment was set for 30 participants or thematic saturation, 
whichever was attained first. The study ran from October 
2017 to February 2018. All transcripts were analysed by 
MAM, and four transcripts (representing 25% of the 
total transcripts) were independently second- coded by 
another researcher (CBK), as recommended by MacPhail 
et al.22 Discrepancies were resolved through consensus 
discussion.
Patient and public involvement
All study materials (recruitment flyer, participant infor-
mation sheet, consent form, interview topic guide, GPP 
consultation example and online questionnaire) were 
reviewed by the AUKCAR Patient Advisory Group (PAG) 
prior to study commencement. Members of the PAG were 
adults with asthma. Their feedback, often regarding word 
choice and text length, was incorporated into the study 
materials.
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Table 1 Demographic characteristics and asthma history
Characteristics (n=17) Frequency, n (%)
Gender
  Female 10 (59)
  Male 7 (41)
Age in years
  18–29 5 (29)
  30–39 7 (41)
  40–49 2 (12)
  50–59 –
  60–69 2 (12)
  70+ 1 (6)
Recruitment channel
  Asthma UK newsletter 7 (41)
  Hospital 1 (6)
  Social media 3 (17)
  University College London newsletter 3 (18)
  Word of mouth 3 (18)
Self- reported asthma severity
  Mild 9 (53)
  Moderate 4 (24)
  Severe 3 (17)
  Prefer not to disclose 1 (6)
Self- reported hospitalisations for asthma (previous 12 
months)
  0 11 (65)
  1–4 3 (17)
  5–10 3 (17)
Self- reported GP visits for asthma (previous 12 months)
  0 2 (12)
  1–10 13 (76)
  10–20 2 (12)
GP, general practitioner.
reSultS
Thematic saturation was reached with 17 participants 
(table 1). The median interview length was 42 min 
(ranging from 30 to 58 min). The participant sample 
was 59% female, with most participants (41%) aged 30 
to 39 years and recruited through the Asthma UK news-
letter (41%). The sample included participants with 
self- reported mild (53%), moderate (24%) and severe 
asthma (17%). Three overarching themes (with seven 
subthemes) were identified from the data: building trust 
in pharmacists, filling gaps in current asthma care and 
navigating a strained healthcare system.
theme 1: building trust in pharmacists
Trust in healthcare professionals involves the optimistic 
acceptance of being in a vulnerable situation, knowing 
that one’s interests will be cared for.14 For participants, 
opinions of the new service were based on the level of 
trust they placed in pharmacists. Trust was built over time, 
based on perceived clinical competency and through 
a benchmarking process, which form the subthemes 
discussed below.
Building trust over time
Participants highlighted that trust in any healthcare 
professional builds through consistent contact over time. 
Some participants felt hesitant about the new service 
because it meant deviating from their usual trusted 
healthcare professional, suggesting a preference for usual 
care over new initiatives to maintain the quality of their 
asthma care.
‘I don’t really know, I think I’d prefer a doctor (to 
talk to about my asthma). It’s the way it’s always been.’
– P15, male, 30–39 years, mild asthma
Building trust based on perceived clinical competency
When asked about specific criteria for trust, partici-
pants discussed pharmacists’ clinical competency. This 
included pharmacists’ asthma- specific and broad clinical 
knowledge. Support for the new service was high when 
pharmacists were viewed as knowledgeable.
‘So I know that in the pharmacy role they’re very 
knowledgeable. So if (adherence support for asthma) 
is something they want to do then why not? I have a 
lot of faith in somebody who’s got a lot of knowledge 
in something.’
– P8, female, 30–39 years, severe asthma
Some participants believed that pharmacists would 
need extensive additional training to develop the knowl-
edge needed for the new service. Their main concern was 
that pharmacists were too medication- focused and there-
fore lacked broader clinical skills.
‘…it could be that the (medication) side- effects are 
something else entirely. So (pharmacists) would be 
kind of completely thinking down the asthma route, 
‘it might just be that you’re taking an inhaler that you 
feel side- effects’…but what if it turns out you actually 
have cancer?’
– P17, male, 18–29 years, mild asthma
Building trust through a benchmarking process
None of the participants had previous experiences with 
GPPs, with some participants questioning the differ-
ences between GPPs and community pharmacists. Many 
participants engaged in a benchmarking process: using 
their trust and previous experiences of other healthcare 
professionals to gauge how much they could trust a GPP. 
Common reference points included community pharma-
cists, respiratory consultants, nurses, GPs and paramedics.
‘…I know (pharmacist support) is there but I still 
don’t understand it with (brittle) asthma because I 
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still get wary. If paramedics have never heard of it and 
don’t know what they’re doing, how’s a pharmacist 
going to hear of it?’
– P2, female, 30–39 years, severe asthma
‘I would much rather go to a pharmacist than to a 
nurse to discuss the medication issues that I was hav-
ing… I can see an asthma nurse to discuss medica-
tion, and I was like ‘Really? What do nurses know 
about…not to be rude, but what do they know about 
medication more than my specialist who prescribed 
it?’
– P4, female, 30–39 years, mild asthma
theme 2: filling gaps in current asthma care
Participants’ opinions of GPPs were also informed by 
perceived gaps in their current asthma care. Partici-
pants evaluated the new service’s place in their current 
care based on potential role overlap between GPPs and 
other healthcare professionals, continuity of care and 
medication- specific support.
Potential role overlap
Participants that saw potential role overlap between GPPs 
and other healthcare professionals were more sceptical of 
the new service.
‘I think if I was having an annual asthma review I 
wouldn’t need to use the pharmacist’s service as well, 
but it might be an alternative to the annual asthma 
review…’
– P3, male, 70+years, mild asthma
However, other participants clearly delineated the GPP 
role, and these participants often recommended ways to 
integrate pharmacists into their care.
‘If you’re asking a GP, you’ve got maybe five, ten min-
utes… If you know you’ve got another ten or fifteen 
minutes with this pharmacist… for asking all these 
questions…with the GP you can concentrate on the 
problem and get that sorted, and then go see the 
pharmacist and discuss the medication.’
– P5, female, 60–69 years, moderate asthma
Continuity of care
Participants with self- reported severe asthma often had 
multiple healthcare professionals involved in their care 
(eg, respiratory consultants, GPs and asthma nurses). 
When asked about the new service, some participants 
felt concerned about involving an additional healthcare 
professional in their care. This was unrelated to their 
views on pharmacist competency and was usually influ-
enced by previous experiences of inadequate continuity 
of care due to a lack of communication between health-
care professionals.
‘(Pharmacists) always say speak to your GP but then 
the GP tells you to speak to the pharmacist because 
they’re supposed to know more about drugs than 
what they are…and then you’re somewhere in the 
middle…’
– P2, female, 30–39 years, severe asthma
Medication-specific support
Other participants with severe asthma who spoke about 
being on multiple medications and/or having other 
health concerns welcomed the service. This enthusiasm 
came from the fact that they identified gaps in their 
current care that they believed could be filled by pharma-
cists as medication experts.
‘…just having contact with someone who actually…
knows about the medication, like they know how they 
work and what the potential side effects are going to 
be and interactions…it’s that knowledge that a GP 
wouldn’t necessarily have time to tell you all about…’
– P6, female, 30–39 years, severe asthma
‘…I’m trying to conceive at the moment so…and 
I thought I don’t want to be taking anything that’s 
unnatural or steroid- y…I did ask the respiratory 
consultant (about asthma medications and In Vitro 
Fertilisation) but he didn’t know…’
–P8, female, 30–39 years, severe asthma
Some participants felt that GPPs should have an inde-
pendent prescribing qualification to fulfil their role as 
medication experts. They worried that the new service 
might contribute to the burden on patients and/or the 
healthcare system and that independent pharmacist 
prescribers would minimise the risk of this happening.
‘For me, it would just be down to whether or not 
(pharmacists) are able to prescribe. I don’t imagine 
that they wouldn’t have the knowledge that was re-
quired…It’s just if I had to then see a doctor to be 
prescribed a different medication, I’d rather just go 
to see the doctor instead.’
– P10, female, 40–49 years, mild asthma
theme 3: navigating a strained healthcare system
Participants were acutely aware of the limited resources 
within general practice. They often expressed guilt and 
frustration about booking appointments for asthma. Partic-
ipants never booked appointments just for medication- 
related questions, and their medication- related concerns 
were frequently left unaddressed because other topics 
took priority in a consultation, particularly if the partic-
ipant had multiple comorbidities. The pharmacist- led 
service was welcomed by these participants because they 
felt pharmacists would have more time to focus on their 
medication.
‘…come Monday morning I wouldn’t want to call the 
GP because I know on Monday morning they’re very, 
very busy…I’ll just sort of crack on at home, multi- 
dosing salbutamol and seeing what happens.’
– P8, female, 30–39 years, severe asthma
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‘(GPs) just want you in and out… ‘oh yes, I wanted to 
ask you something else’ but too late now, you’re away. 
That’s how you feel.’
–P1, female, 30–39 years, mild asthma
The hierarchy of healthcare professionals
Many participants constructed a hierarchy of healthcare 
professionals with GPs at the top, followed by nurses 
and finally pharmacists. This hierarchy determined the 
importance of each healthcare professional’s time. Severe 
health concerns justified booking a GP appointment, 
while non- urgent concerns were viewed as more suitable 
for pharmacists.
The hierarchy of healthcare professionals affected opin-
ions of GPPs in both directions. Some participants were 
enthusiastic about the new service because they believed 
it would lessen the workload of GPs and nurses. For these 
participants, seeing a pharmacist (the healthcare profes-
sional further down the hierarchy) felt less intimidating 
and formal, slightly easing concerns about taking up valu-
able appointment time.
‘…to be honest, GPs have bigger problems to deal 
with…[they’re] dealing with people with, you know, 
life threatening illnesses, then actually seeing the 
standard case of asthma or an asthma check- up isn’t 
the best use of (their) time.’
– P16, male, 18–29 years, moderate asthma
‘It feels less formal, I think, when you’re with a phar-
macist than when you’re in the doctor’s…sometimes 
when you go to the doctor’s, you’re kind of clock 
watching…’
– P10, female, 40–49 years, mild asthma
Others felt that pharmacists could not extend into a clin-
ical role similar to GPs and nurses, with some suggesting a 
triage- like function to safeguard GP time.
‘I never feel as though a pharmacist is a nurse, if you 
see what I mean. A nurse has practical hands- on expe-
rience of trying to make people better. The pharma-
cist is one who deals with the theory of medication.’
–P9, male, 60–69 years, undisclosed asthma severity
‘… the pharmacist has seen you and if there’s com-
munication between the pharmacist and the GP, so 
that I guess it would help the GPs prioritise who they 
saw…’
–P11, female, 40–49 years, moderate asthma
However, pharmacists themselves were also viewed as 
a limited resource. Many participants supported moving 
pharmacists from community pharmacies to general 
practice because they experienced inadequate care in 
busy community pharmacies. Others were concerned that 
pharmacist- led adherence support with a wide scope (ie, 
for multiple long- term conditions) would limit access for 
people with asthma.
‘If (pharmacists) weren’t running a community phar-
macy, if they were linked in, if they worked within the 
GP surgery with a lot of time, then yes, I don’t see 
how (a lack of time) would be an issue’
– P12, female, 30–39 years, mild asthma
‘…my worry is if a pharmacist has to do (adherence 
support in general practice) for asthma, what other 
long- term conditions will they have to do it for?’
– P6, female, 30–39 years, severe asthma
DiSCuSSiOn
This is the first in- depth exploration of the perspectives of 
adults with asthma on pharmacist- led adherence support 
in general practice. This focused exploration identified 
potential barriers to service uptake and has the potential 
to help further refine and tailor the GPP service as it is 
rolled out.
interpretation of findings
Trust played an important role in participants’ initial 
perspectives of GPP- led care—it was an essential compo-
nent of the patient- pharmacist relationship and it 
informed participants’ views of pharmacists’ role in 
asthma care. These findings suggest that general aware-
ness of the existence of pharmacist- led services is insuffi-
cient to encourage service uptake.
Participants based their trust in pharmacists on 
perceived clinical competency and comparisons with 
other trusted healthcare professionals (eg, GPs and 
nurses), guided by perceptions of pharmacists’ position in 
the hierarchy of healthcare professionals. These findings 
may suggest that explicit endorsement of GPP- led care 
by other trusted healthcare professionals might improve 
service uptake among adults with asthma. Reassurance 
and support from GPs and nurses may address some of 
the concerns raised by study participants, including those 
about fragmented care, pharmacists’ clinical competency 
and potential role overlap.
Support for GPP- led care did not seem to differ based 
on participants’ age, gender or self- reported asthma 
severity—there was a variety of views in each group of 
participants. However, participants who spoke about 
being on multiple medications and/or having additional 
health concerns seemed to be more open to pharmacist 
input, perhaps because they felt current asthma care was 
unable to meet these additional needs. Targeting this 
group of adults with asthma may improve service uptake 
in the future.
Strengths and limitations
The qualitative method in this study captured the complex 
processes behind people’s initial opinions of GPPs. The 
combination of recruitment channels produced variation 
in the sample in terms of age, self- reported asthma severity 
and healthcare utilisation. Telephone- based interviews 
enabled recruitment across the UK without increasing 
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participant burden, thus increasing study accessibility 
for participants with severe asthma and limited travel 
capacity. In addition, telephone- based interviews can 
produce data of higher quality compared with face- to- 
face interviews when sensitive topics (eg, long- term condi-
tions) are discussed.23
The participant sample may however not have captured 
the views of all adults with asthma because it consisted 
primarily of people with self- reported mild asthma 
(53%) and people recruited through Asthma UK (41%). 
Thematic saturation may have been reached due to the 
relative homogeneity of the participant sample. The 
participants recruited through Asthma UK may have 
had a stronger interest in asthma care or pharmacist- led 
support and may therefore have been more supportive 
of the new service compared with the general population 
with asthma. However, if scepticism of the new service 
exists among people who are more engaged in their care, 
then the findings may be amplified in the general popu-
lation with asthma who may have less interest in asthma 
care.
A major drawback of the study is that none of the partic-
ipants had experienced a GPP consultation directly, with 
some participants recruited from Scotland and Northern 
Ireland where the GPP scheme does not exist. While the 
consultation description that participants were asked 
to read was based on real work by a clinical respiratory 
pharmacist working in general practice, study findings 
can only be used to understand patients’ initial views of a 
GPP- led service. These participants represent the general 
population with asthma who would initially need to be 
convinced to engage with the service. Addressing some of 
the concerns identified by participants may help improve 
the uptake of existing GPP- led care among adults with 
asthma. However, participants’ views may change over 
time and could potentially be influenced by direct 
personal experience with a GPP consultation.
Comparison with existing literature
There is limited research on patient perspectives of GPPs 
because the care model is relatively new. However, find-
ings from this study align with those from community 
pharmacy- based research, suggesting that people with 
asthma may not differentiate between pharmacy sectors.
Findings align with work by Gidman et al,13 who found 
that people were hesitant about deviating from their 
usual trusted care model (often a GP). However, two of 
the older participants in this study were open to GPP- led 
care, in contrast to previous research that suggests that 
older patients may be less likely to accept an expanded 
pharmacist role.24
In line with the present study’s findings, previous 
research with general members of the public and people 
with asthma found that other trusted healthcare profes-
sionals (eg, GPs and nurses) were used as benchmarks to 
inform opinions of community pharmacist- led services.13 20 
Similarly, Naik Panvelkar et al20 found that previous posi-
tive experiences with community pharmacists raised 
expectations for other pharmacist- led services in a popu-
lation of people with asthma.
Participants’ views of the gaps in their current asthma 
care shaped their perspectives of GPPs. Similarly, 
Boyd et al25 found that recipients of the New Medicine 
Service welcomed pharmacists’ recommendations if 
they addressed a concern directly raised by the patient. 
While asthma care guidelines recommend a multidisci-
plinary approach in treating difficult asthma, the present 
study suggests that some people with self- reported severe 
asthma were hesitant to include another healthcare 
professional due to issues with continuity of care.26 In 
line with previous research, the hierarchy of healthcare 
professionals influenced perspectives of pharmacists 
expanding further into clinical roles.13 15 However, this 
study also found that the hierarchy increased support for 
pharmacist- led care to reduce the burden on GPs/nurses.
implications for research and practice
As the GPP model is rolled out, future studies could be 
conducted using in- depth interviews with people with 
asthma after they have experienced a GPP- led consul-
tation. These interviews could establish if interpersonal 
factors (ie, rapport with the pharmacist) have an impact 
on patient perspectives. Ethnographic observations of 
pharmacist- led consultations and the general practice 
team will help assess pharmacists’ integration and its 
effect on continuity of care for asthma patients. Future 
recruitment should aim for greater variation in partici-
pants (eg, self- reported asthma severity) through various 
recruitment channels, with additional efforts to look for 
discordant voices when thematic saturation is reached.
Findings from this study could be implemented in 
efforts to increase service uptake among people with 
asthma. Given the benchmarking process used to estab-
lish trust in pharmacists, comparisons between GPPs and 
other healthcare professionals could be used to inform 
and engage the public. For example, public campaigns 
highlighting the differences and similarities between GPs 
and GPPs may help the public differentiate the phar-
macist role and understand the added value of the new 
service within asthma care.
Participants wanted GPPs to have broad clinical 
skills and a prescribing qualification. Encouragingly, 
the Centre for Pharmacy Postgraduate Education has 
already included these components in their GPP training 
pathways.27
Although the hierarchy of healthcare professionals 
sometimes prevented pharmacists from being perceived 
as clinicians, it also made GPP appointments appear less 
formal and intimidating to access. Participants felt more 
comfortable making an appointment with a pharmacist 
for medication- related questions. This is encouraging 
because the new service may encourage people with 
asthma to address medication- related concerns that may 
be barriers to medication adherence.28
While the perspectives of people with asthma explored 
in this study show that the GPP model has promise, they 
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identified several barriers to optimal patient engage-
ment and service implementation that will need to be 
addressed for the service to be effective. Meeting patient 
expectations will be the first crucial step in ensuring the 
programme’s long- term benefit and reducing the pres-
sure on general practice in England.
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